Today it was reported that the CEO of Zoetis (ZTS), Juan Ramon Alaix, exercised options to sell 312,109 ZTS shares for a total transaction value of $29.36M.
In addition to Juan Ramon Alaix, 2 other ZTS executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Zoetis’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $1.56 billion and quarterly net profit of $345 million. In comparison, last year the company earned revenue of $1.46 billion and had a net profit of $81 million. ZTS’s market cap is $45.19B and the company has a P/E ratio of 32.09. Currently, Zoetis has an average volume of 2.07M.
Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $101.25, reflecting a 5.7% upside.
The insider sentiment on Zoetis has been negative according to 37 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.
